<!-- Shared CTAP objectives - used by executive brief, suite briefs, and RTA -->
<!-- Source of truth: Google Sheets CFI_CTAP_Data > Objectives tab -->
<!-- Last synced: 2026-01-06 -->

## Core Objectives (By 2031)

1. **Reduce trial startup by 40-50%** (from 12+ months to 6 months; stretch goal: 4 weeks via CRAIDL)
2. **Double recruitment efficiency** with explicit targets: 15% Indigenous, 20% rural, pediatric participation
3. **Enable 5+ first-in-human trials** through Canada's first academic Challenge Trial Unit and ACTM cell therapy; 2+ products advancing to CMPC scale-up
4. **Integrate biospecimens and RWD** in 70%+ of interventional trials with Connect Care linkage
5. **Deploy 8 CRAIDL AI agents** as national infrastructure via ACT-AEC; adopted by 5+ institutions
6. **Establish pandemic preparedness capacity** supporting PRAIRIE Hub vaccine programs (saRNA, Comparative Vaccine Platform)
7. **Create a national backbone** serving 10+ institutional partners across ACT-AEC, PRAIRIE Hub, RareKids-CAN
8. **Train 150+ HQP** in AI-enabled trial design (20% Indigenous/underrepresented); training curriculum adopted nationally
